Dexcom Inc. Stock
Dexcom Inc. Stock
A loss of -1.580% shows a downward development for Dexcom Inc..
The stock is one of the favorites of our community with 44 Buy predictions and 1 Sell predictions.
With a target price of 77 € there is a positive potential of 26.19% for Dexcom Inc. compared to the current price of 61.02 €.
Our community identified positive and negative aspects for Dexcom Inc. stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Dexcom Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Dexcom Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Dexcom Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Dexcom Inc. | -1.580% | 5.120% | -1.478% | -26.947% | 8.165% | -41.154% | -26.844% |
| Teleflex Inc. | 3.700% | 12.000% | 10.112% | -40.964% | -3.922% | -55.856% | -68.790% |
| Dentsply Sirona Inc. | -1.220% | -2.521% | -3.886% | -40.620% | 10.897% | -67.909% | -75.585% |
| Idexx Laboratories Inc. | 0.410% | 1.774% | -8.296% | 24.602% | -7.732% | 20.080% | 22.064% |
Comments
DexCom (NASDAQ:DXCM) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $80.00 price target on the stock, down previously from $82.00.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom (NASDAQ:DXCM) had its price target lowered by analysts at Wells Fargo & Company from $93.00 to $85.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom (NASDAQ:DXCM) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $85.00 price target on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
News
DexCom Stock Just Fell to a 5-Year Low. Is It a No-Brainer Buy at This Price?
It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you
1 Spectacular Growth Stock Down 20% to Buy Right Now, According to Wall Street
Since last year, DexCom (NASDAQ: DXCM) has faced a series of issues that have sunk its stock price. The medical device specialist's shares are down 20% over the trailing-12-month period and are
From Dividends to Growth: Why These 3 Stocks Stand Out in 2025
It's rare for an attractive dividend stock also to have growth potential. Most leading dividend distributors have moved past their high-growth days and have transitioned into stable, mature
